The role of SUMOylation in liver fibrosis has been reported in that coadministration of SUMOylation inhibitors increased the efficacy of farnesoid X receptor agonists against HSC activation and fibrosis [25]. Here, NR1H4 is linked to Hepatic fibrosis.